SoC Chemotherapy

DRUG3 trials

Sponsors

Ludwig-Maximilians - University of Munich, Kathy Miller, Women's Cancer Study Group GmbH

Conditions

Breast CancerER Positive, HER2 Negative Breast CancerEstrogen-receptor-low Breast CancerMetastatic Breast CancerPancreatic CancerTriple Negative Breast CancerTriple-negative Breast Cancer

Phase 2

MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC

TerminatedNCT05114213

Ludwig-Maximilians - University of MunichPancreatic Cancer

Start: 2021-12-15End: 2025-11-11Updated: 2025-12-05

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

RecruitingNCT05846789

Kathy MillerMetastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer +1

Start: 2024-07-02End: 2027-12-01Target: 168Updated: 2026-09-03

Phase 3

NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

Not yet recruitingNCT07178730

Women's Cancer Study Group GmbHBreast Cancer, Triple-negative Breast Cancer

Start: 2026-08-30End: 2033-03-31Target: 765Updated: 2026-08-05

Related Papers

MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC)

Radiation Oncology2022-01-2518 citations